The United States National Institutes of Health (NIH) signed a deal today with the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) that allows manufacturers greater access to key COVID-19 technologies owned by NIH. The licensing agreement offers 11 technologies under transparent, global and non-exclusive licenses. They include “the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics.”
Recent Posts
- In Latest Antitrust Blow for Google, Judge Finds Search Giant Monopolizes Certain Ad Tech Markets
- New USPTO Group to Crack Down on Threats to U.S. Patent System
- IP, Globalization and the Future of Supply Chains: A Conversation with Sonja London | IPWatchdog Unleashed
- IPWatchdog’s New Publication Policy: No Paywall, But No Free Ride
- UPC vs. EPO Oppositions: Lessons from Recent UPC Case Law